China Regenerative Medicine International (HKSE:08158) Revenue : HK$69.49 Mil (TTM As of Jun. 2024)

View and export this data going back to 2001. Start your Free Trial

What is China Regenerative Medicine International Revenue?

China Regenerative Medicine International's revenue for the three months ended in Jun. 2024 was HK$0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2024 was HK$69.49 Mil. China Regenerative Medicine International's Revenue per Share for the three months ended in Jun. 2024 was HK$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.25.

Warning Sign:

China Regenerative Medicine International Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of China Regenerative Medicine International was -58.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -40.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was -19.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was 30.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, China Regenerative Medicine International's highest 3-Year average Revenue per Share Growth Rate was 640.50% per year. The lowest was -95.10% per year. And the median was -13.90% per year.

China Regenerative Medicine International Revenue Historical Data

The historical data trend for China Regenerative Medicine International's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Regenerative Medicine International Revenue Chart

China Regenerative Medicine International Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Revenue

Get a 7-Day Free Trial

19.37

182.14

282.90

41.54

69.49

China Regenerative Medicine International Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24
Revenue	Get a 7-Day Free Trial															54.05	46.04	11.97	-42.57	-

Competitive Comparison of China Regenerative Medicine International's Revenue

For the Biotechnology subindustry, China Regenerative Medicine International's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Regenerative Medicine International's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, China Regenerative Medicine International's Revenue distribution charts can be found below:

* The bar in red indicates where China Regenerative Medicine International's Revenue falls into.

China Regenerative Medicine International Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$69.49 Mil.

China Regenerative Medicine International (HKSE:08158) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

China Regenerative Medicine International Revenue Related Terms

Thank you for viewing the detailed overview of China Regenerative Medicine International's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

China Regenerative Medicine International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Regenerative Medicine International Ltd (HKSE:08158) » Definitions » Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

132 Nathan Road, Suite 2310-18, Miramar Tower, Tsim Sha Tsui, Kowloon, HKG

Website

https://www.crmi.hk

China Regenerative Medicine International Ltd is an investment holding company engaged in the provision of healthcare products and services. Its reportable segments are Aesthetic medical and beauty services and Medical services. The vast majority of the company's revenue is derived from its Aesthetic medical and beauty services segment. Geographically, the People's Republic of China accounts for the majority of the revenue. It also has a presence in Hong Kong.

Executives

Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Wang Chuang	2101 Beneficial owner
Arab Osman Mohammed	2501 Other
Wong Kwok Keung	2501 Other
Lei Changjuan	2101 Beneficial owner
Chang Zhou Shi Zhong Min Xing Kong Qi Ye Guan Li Zi Xun Fu Wu He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Kong Yudong	2101 Beneficial owner
Chang Zhou Shi Yao Guang Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Li Ren	2201 Interest of corporation controlled by you
Nat-ace Wood Industry Ltd. (formerly Known As Forerunner Technology Limited)	2201 Interest of corporation controlled by you
All Favour Holdings Limited	2101 Beneficial owner
Deng Shufen	2202 Interest of your spouse
Dai Yumin	2201 Interest of corporation controlled by you
Wang Xiaogang	2101 Beneficial owner
China Orient Asset Management Co., Ltd.	2106 Person having a security interest in shares

China Regenerative Medicine International Headlines

No Headlines